Abbott receives warning letter for Norvir promos
A pricing chart for Abbott's HIV therapy Norvir (ritonavir) misrepresents the dose and cost of therapy, a June 10 FDA 1warning letter states. The chart compares "a subtherapeutic dose of Norvir (100 mg once daily) to the labeled dosing regimens of other antiretroviral agents," FDA said. "The cost chart is false or misleading...because it claims that Norvir has the lowest daily cost of all antiretroviral drugs and minimizes the risks of Norvir." NIH is considering compulsory licensing for Norvir (2"The Pink Sheet" May 31, 2004, p. 3)...
You may also be interested in...
FDA is asking Abbott to correct some of the statements made by the company in defense of the price increase for Norvir (ritonavir)
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.